Cannabis Science sees strong future for its products, despite rejection of California's Proposition 19

Cannabis Science (OTC Bulletin Board:CBIS.ob), a US biotech company developing pharmaceutical cannabis products, says that, regardless of the outcome of Proposition 19 in California and other marijuana-related electoral issues throughout the country, it is apparent that that the Cannabis Science Food and Drug Administration clinical trials initiatives are more important than ever, as the demand for the firm’s pharmaceutical products for critical ailments may reach an all time high.

Along with the US mid-term elections last Tuesday, California voters rejected Proposition 19, an initiative which would have legalized the recreational use of specific amounts of marijuana. However, even if Proposition 19 passed, there was no guarantee that federal law would have accepted the result.

Cannabis Science said it understands that its investors realize the importance of providing FDA-cleared pharmaceutical products for much needed treatments for serious illnesses, such as cancer, AIDS, chronic pain, PTSD, etc. It is unrelated to the efforts to legalize the recreational use of marijuana, it added.